Sanara MedTech Inc. (SMTI) Market Cap
Sanara MedTech Inc. has a market capitalization of $190.4M.
Financials based on reported quarter end 2025-12-31
Price: $20.77
▲ 0.99 (5.01%)
Market Cap: 190.40M
NASDAQ · time unavailable
CEO: Seth D. Yon
Sector: Healthcare
Industry: Medical - Instruments & Supplies
IPO Date: 1994-04-07
Website: https://sanaramedtech.com
Sanara MedTech Inc. (SMTI) - Company Information
Market Cap: 190.40M · Sector: Healthcare
Sanara MedTech Inc. develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. It offers CellerateRX Surgical Activated Collagen powder and gel that are used in a range of surgical specialties to help promote patient healing; Biako's Antimicrobial Skin and Wound Cleanser, a patented product that disrupts extracellular polymeric substances to eradicate mature biofilm microbes; Biako's Antimicrobial Wound Gel, an antimicrobial hydrogel wound dressing helps against planktonic microbes, as well as immature and mature biofilms; and Biako's Antimicrobial Skin and Wound Irrigation Solution. The company also provides HYCOL Hydrolyzed Collagen Powder and Gel, a medical hydrolysate of Type I bovine collagen for the management of full and partial thickness wounds, including pressure ulcers, venous and arterial leg ulcers, and diabetic foot ulcers. In addition, it develops FORTIFY TRG, a freeze-dried, multi-layer small intestinal submucosa extracellular matrix sheet; FORTIFY FLOWABLE extracellular matrix, an advanced wound care device; and VIM Amnion Matrix, a single layer sheet of amnion tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.
Analyst Sentiment
Based on 1 ratings
Analyst 1Y Forecast: $43.00
Average target (based on 2 sources)
Consensus Price Target
Low
$32
Median
$32
High
$32
Average
$32
Potential Upside: 54.1%
Price & Moving Averages
Related Companies in Healthcare
Management’s tone is upbeat and execution-focused: they highlight margin expansion (~+200 bps FY, ~+175 bps Q4), strong FY cash generation ($6.8M operating cash), and reiterated FY2026 revenue growth guidance ($116M–$121M) plus a clearly stated Q1 2026 range ($26.7M–$27.2M). In the Q&A, the pressure point is BIASURGE demand generation post–Vizient Innovative Technology contract. The analyst is essentially asking how much is “inorganic” GPO volume versus organic account growth. Seth doesn’t quantify a % split, but clearly reframes the timeline: Vizient grants contracted access to 1,800+ facilities starting Jan 1, 2026, yet adoption remains facility-education constrained (“one facility at a time”), implying growth ramps over time rather than instantly. On CellerateRX, the analyst probes economics/reimbursement impact; management counters with a key hard assurance—no reimbursement risk and the product is a supply cost inside DRG—suggesting evidence strengthens hospital relationships more than it changes reimbursement mechanics.
Growth Catalysts
- BIASURGE expansion via Vizient Innovative Technology contract effective January 1, 2026 (access to 1,800+ facilities at contracted pricing)
- Distributor network growth (over 450 contracted distributors at end of 2025 vs 350 at end of 2024) supporting continued soft-tissue growth
- New facility penetration (target achieved: 1,450+ facilities by end of 2025 vs 1,300 in 2024; products contracted/approved in 4,000+ facilities at year-end)
- Ongoing surgeon-user adoption inside existing facilities (penetration described as still “relatively low,” implying runway)
Business Development
- Vizient Innovative Technology program: BIASURGE awarded an Innovative Technology contract; contract provides access to ~1,800 health care facilities starting January 1, 2026
- BMI partnership for OsStic: on track to introduce synthetic injectable bone bio-adhesive in the U.S. in Q1 2027 (FDA Breakthrough Device status referenced)
- Independent distributors: partnership model credited for growth (450+ contracted distributors at year-end 2025)
Financial Highlights
- FY2025 net revenue: $103.1M (+19% YoY), first time exceeding $100M
- Q4 2025 net revenue: $27.5M (+5% YoY); “high end” of both prior press-release range (Jan 23, 2026) and expectations from prior call (Nov 2025)
- BIASURGE normalization note: Q4 2024 included ~$1.8M of BIASURGE sales tied to Hurricane Helene disruption; excluding that, Q4 2025 net revenue growth was +13% YoY
- Gross margin expansion: ~+200 bps to 93% for FY2025; Q4 gross margin: ~+175 bps to 93%
- Profitability: net loss from continuing operations reduced by $1.5M (80%); adjusted EBITDA improved by $7.9M (86%) to $17M in FY2025
- Cash flow: cash provided by operations $6.8M in FY2025 vs $24K used in FY2024 (management notes $9M cash used related to THP included in this $6.8M estimate)
- Q4 operating income: $1.1M vs $2.3M prior year; excluding a $1.8M noncash impairment charge, operating income increased $0.6M (28%) to $2.9M
- Operating-expense drivers: $1.8M noncash impairment (IP asset write-down) + $1.2M R&D increase for soft tissue repair product enhancements
- Debt/cash: $16.6M cash and $46M long-term debt at Dec 31, 2025 (cash up vs $15.9M; long-term debt up vs $30.7M)
Capital Funding
- No buyback disclosed
- Long-term debt increased to $46.0M at Dec 31, 2025 from $30.7M at Dec 31, 2024
- Liquidity commentary: management stated comfort with balance sheet liquidity in 2026 given $16.6M cash and expected operating cash flows
- THP cash use: $5.3M in 2H 2025 (below previously guided $5.5M to $6.5M range); management expects no material THP cash spend going forward
Strategy & Ops
- THP wind-down: “substantially complete” by end of 2025; THP operations classified as discontinued operations
- BIASURGE commercialization pace hurdle: education/training at facility level described as necessarily slow (“one facility at a time” historically), now accelerated by being on-contract with 1,800+ accounts
- Field sales expansion plan: during Q1 2026, targeted investments to expand rep coverage in key territories; new reps expected to become increasingly productive over the rest of 2026
- R&D/IP: additional patent-related progress noted (11 provisional filings converted to nonprovisionals in 2025; 3 additional provisionals filed for CellerateRX components)
Market Outlook
- FY2026 net revenue guidance reaffirmed: $116M to $121M (+13% to +17% YoY vs $103.1M FY2025)
- Q1 2026 net revenue expectation: ~$26.7M to $27.2M (+14% to +16% YoY)
Risks & Headwinds
- Q&A operational hurdle: Even with Vizient on-contract status, management emphasized it still takes time to educate at the facility level (slow facility-by-facility adoption dynamic).
- Analyst question did not cite tariffs/macro; no specific macro or tariff mitigation steps mentioned in the transcript.
Sentiment: POSITIVE
Note: This summary was synthesized by AI from the SMTI Q4 2025 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.
Fundamentals Overview
📊 AI Financial Analysis
Powered by StockMarketInfo"For the fiscal year ending December 31, 2025, SMTI reported revenues of $27.52M but faced a net loss of $1.61M. The company's operating cash flow stood at $3.95M, indicating some operational effectiveness despite the low profitability. However, free cash flow remained robust at $3.86M, suggesting efficient capital management. On the balance sheet, total assets were $39.40M against total liabilities of $48.39M, leading to total equity of $5.93M and significant net debt of $31.61M, a possible concern for leverage. The stock has performed poorly over the past year, with a price drop of 49.34%, reflecting a challenging market sentiment. With no dividends distributed, shareholder returns have primarily stemmed from price changes, contributing to an overall negative sentiment. The price is currently at $18.08, well below its target consensus of $49, indicating potential for recovery if operational challenges can be addressed and market conditions improve."
Revenue Growth
Revenue of $27.52M indicates moderate growth potential but needs improvement.
Profitability
Negative net income of -$1.61M reflects struggles with profitability.
Cash Flow Quality
Strong free cash flow of $3.86M suggests decent cash management.
Leverage & Balance Sheet
Total liabilities exceed total assets, indicating high leverage.
Shareholder Returns
Significant 1-year price decline of 49.34%, no dividends paid.
Analyst Sentiment & Valuation
Price far below target consensus of $49 signals potential undervaluation.
Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.